Epoprostenol

DRUG5 trials

Sponsors

National Center for Research Resources (NCRR), Free University Medical Center, GlaxoSmithKline, Actelion, Universitaire Ziekenhuizen KU Leuven

Conditions

Acute Pulmonary EmbolismCardiovascular DiseaseHypertension, PulmonaryPulmonary Arterial HypertensionReperfusion Injury

Phase 2

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

CompletedNCT02251041

Universitaire Ziekenhuizen KU LeuvenReperfusion Injury

Start: 2014-09-30End: 2019-08-31Updated: 2024-08-23

Phase 3

Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension

CompletedNCT01470144

ActelionPulmonary Arterial Hypertension

Start: 2011-06-01End: 2015-07-01Updated: 2025-02-04

Phase 4

Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension

CompletedNCT00004754

National Center for Research Resources (NCRR)Hypertension, Pulmonary

Start: 1993-08-31Updated: 2005-06-24

Epoprostenol in Pulmonary Embolism

CompletedNCT01014156

Free University Medical CenterAcute Pulmonary Embolism

Start: 2004-01-31End: 2006-06-30Updated: 2009-11-16

Unknown Phase

Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg

CompletedNCT01387191

GlaxoSmithKlineCardiovascular Disease

Start: 1999-08-31End: 2009-07-31Updated: 2017-05-16

Related Papers

Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant

JAMA Network Open2023-02-2811 citations

No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.

2010-03-3018 citations